DE69926251D1 - Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten - Google Patents

Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten

Info

Publication number
DE69926251D1
DE69926251D1 DE69926251T DE69926251T DE69926251D1 DE 69926251 D1 DE69926251 D1 DE 69926251D1 DE 69926251 T DE69926251 T DE 69926251T DE 69926251 T DE69926251 T DE 69926251T DE 69926251 D1 DE69926251 D1 DE 69926251D1
Authority
DE
Germany
Prior art keywords
endothelial cells
tumor associated
mutants
adenoviral mutants
associated endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69926251T
Other languages
English (en)
Other versions
DE69926251T2 (de
Inventor
Angelica Williams
Carla Heise
Meisa Propst
Adam Sampson-Johannes
David Kirn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyx Pharmaceuticals Inc
Original Assignee
Onyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharmaceuticals Inc filed Critical Onyx Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69926251D1 publication Critical patent/DE69926251D1/de
Publication of DE69926251T2 publication Critical patent/DE69926251T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69926251T 1998-10-26 1999-10-15 Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten Expired - Lifetime DE69926251T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10570198P 1998-10-26 1998-10-26
US105701P 1998-10-26
US12130099P 1999-02-23 1999-02-23
US121300P 1999-02-23
PCT/US1999/024144 WO2000024408A1 (en) 1998-10-26 1999-10-15 Method for killing tumor and tumor associated endothelial cells using adenoviral mutants

Publications (2)

Publication Number Publication Date
DE69926251D1 true DE69926251D1 (de) 2005-08-25
DE69926251T2 DE69926251T2 (de) 2006-05-24

Family

ID=26802854

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69926251T Expired - Lifetime DE69926251T2 (de) 1998-10-26 1999-10-15 Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten

Country Status (11)

Country Link
US (1) US20020037274A1 (de)
EP (1) EP1121137B1 (de)
JP (1) JP2004517798A (de)
CN (1) CN1333689A (de)
AT (1) ATE299708T1 (de)
AU (1) AU775611B2 (de)
CA (1) CA2348634A1 (de)
DE (1) DE69926251T2 (de)
DK (1) DK1121137T3 (de)
ES (1) ES2245831T3 (de)
WO (1) WO2000024408A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175362A1 (en) * 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
DE60229856D1 (de) * 2001-01-12 2008-12-24 Sbarro Health Res Organization
US7906311B2 (en) * 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US20040191761A1 (en) * 2003-03-27 2004-09-30 Routes John M. Modified adenoviral E1A constructs and methods of use thereof
KR100746122B1 (ko) 2004-05-10 2007-08-03 연세대학교 산학협력단 Ｒｂ-결합능이 상실된 개선된 종양세포-특이 세포살상능을 나타내는 재조합 아데노바이러스
CN101617052A (zh) 2007-01-30 2009-12-30 特兰斯吉恩股份有限公司 用于免疫的乳头瘤病毒e2多肽
ES2536747T3 (es) 2009-01-20 2015-05-28 Transgene Sa ICAM 1 soluble como biomarcador para predicción de respuesta terapéutica
NZ595290A (en) 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
RU2555340C2 (ru) 2009-04-17 2015-07-10 Трансжене Са Биомаркер для мониторинга пациентов
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
JP5650212B2 (ja) 2009-07-10 2015-01-07 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者を選択するためのバイオマーカーおよび関連方法
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP3390428B1 (de) 2016-02-23 2019-09-25 Salk Institute for Biological Studies Test mit hohem durchsatz zur messung der adenovirusreplikationskinetik
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
AU682854B2 (en) * 1993-02-16 1997-10-23 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1999031261A1 (en) * 1997-12-12 1999-06-24 Onyx Pharmaceuticals, Inc. SELECTIVE KILLING AND DIAGNOSIS OF p53+ NEOPLASTIC CELLS
EP1230378B1 (de) * 1999-11-15 2007-06-06 Onyx Pharmaceuticals, Inc. Ein oncolytisches adenovirus
US7078030B2 (en) * 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus

Also Published As

Publication number Publication date
US20020037274A1 (en) 2002-03-28
WO2000024408A1 (en) 2000-05-04
DE69926251T2 (de) 2006-05-24
ATE299708T1 (de) 2005-08-15
AU775611B2 (en) 2004-08-05
CN1333689A (zh) 2002-01-30
EP1121137A1 (de) 2001-08-08
JP2004517798A (ja) 2004-06-17
CA2348634A1 (en) 2000-05-04
DK1121137T3 (da) 2005-11-14
ES2245831T3 (es) 2006-01-16
EP1121137B1 (de) 2005-07-20
AU6518799A (en) 2000-05-15

Similar Documents

Publication Publication Date Title
DE69926251D1 (de) Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten
ZA200005475B (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with anglogenesis inhibitor.
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
EP1322307A4 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
EP1180932A4 (de) Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
EP1807107A4 (de) Stabiliserte aptamere für einen aus plättchen gewonnenen wachstumfaktor und ihre verwendung als krebstherapiemittel
DE60238435D1 (de) Gezielte thrombose durch gewebefaktor polypeptiden
EP1409653A4 (de) In menschlichen zielkrebszellen selektiv replizierende virusmutanten
DE69730153D1 (de) EHV-1 Vektoren
Matsumoto et al. NK4 gene therapy combined with cisplatin inhibits tumour growth and metastasis of squamous cell carcinoma
DK1071805T3 (da) Adenovirusvektorer til sygdomsbehandling
Nagano et al. Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: novel concepts for successful cytokine gene therapy
WO2001072341A3 (en) Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
MXPA02010974A (es) Metodos para inhibir la proliferacion e inducir apoptosis en celulas carcerosas.
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
ATE417926T1 (de) Zusammensetzungen zur modulierung der länge von telomeren
Nanda et al. Clinical trials of adenoviral-mediated suicide gene therapy of malignant gliomas
Manegold Chemotherapy in stage I/II NSCLC and projects of the EORTC—lung cancer group for early stage lung cancer
WO2002059609A3 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
ITMI980179A1 (it) Proteine ricombinanti derivate da hgf e msp
Jacobsen et al. Advances in Gene Therapy for Bladder Cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition